サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：膀胱がんの世界市場の評価：タイプ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
市場調査レポート
商品コード
1417600

膀胱がんの世界市場の評価：タイプ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Bladder Cancer Market Assessment, By Types, By Modality, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 225 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
膀胱がんの世界市場の評価：タイプ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年01月29日
発行: Market Xcel - Markets and Data
ページ情報: 英文 225 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の膀胱がんの市場規模は、2023年に45億1,000万米ドル、2031年に68億1,000万米ドルに達し、2024年～2031年の予測期間にCAGRで5.28%の成長が見込まれています。膀胱がんの有病率の増加、老年人口の増加、診断と治療手法の技術の進歩、政府の取り組み、研究開発資金の増加など、数多くの要因が世界の膀胱がん市場を推進しています。膀胱がんの有病率の向上は、世界の膀胱がん市場の主な促進要因です。

膀胱がんは、世界で10番目に多いがんとなっています。これは高齢化や環境発がん物質への曝露の増加などのさまざまな要因によるものと考えられます。世界人口の高齢化に伴い、膀胱がんのリスクは増加し、診断と治療オプションに対する需要が高まっています。医療インフラの進歩やアクセス性の向上が、世界の膀胱がん市場の成長に寄与しています。医療サービスへのよりよいアクセスや、より質の高いケア、先進の施設は、膀胱がん患者の早期発見とよりよい転帰につながります。

イメージング技術、非侵襲性尿検査、分子診断における革新は、早期発見とモニタリングに革命をもたらし、患者の転帰改善につながっています。タバコの消費や工業用化学品への曝露の増加は膀胱がんの発症に重大な役割を果たしており、世界の膀胱がん市場の需要を急増させています。市場では、低侵襲手術法、ロボット支援手術、精密医療など、治療の有効性を向上させ、患者体験を高める技術の進歩が見られます。政府の取り組みと研究資金が市場拡大に寄与しています。臨床試験や医薬品開発を含む膀胱がん研究への投資の増加は、技術革新を促進し、新しい治療法や診断ツールをもたらしています。

膀胱がんの有病率の向上

膀胱がんの発生率と有病率の増加は、世界の膀胱がん市場の拡大に重要な役割を果たしています。膀胱がんは世界で6番目に広く見られるがんであり、男性では10番目に多く、女性では17番目に多いという明確な男女差があります。この高い有病率は、高齢化、環境発がん物質への曝露の増加、個人のライフスタイルの選択などの多くの要因によって形成されています。膀胱がん患者が増加の一途をたどる中、先進の診断技術、治療法、医療に対する需要が高まっています。需要の急増は研究を刺激し、技術革新を促進し、早期発見、より先進の治療、患者ケアの強化に向けた膀胱がん市場への投資を促進します。

技術の進歩

近年の技術の進歩は、世界の膀胱がん市場の進歩において極めて重要です。こうした医療技術の革新は、膀胱がんの診断、治療、モニタリングの方法に革命をもたらしました。これらの技術革新には、低侵襲性の手術法の開発、精度を高めるロボット支援手術の導入、個別化医療アプローチの導入などが含まれます。これらのブレークスルーは、侵襲を減らし回復を速めることで、治療の有効性と全体的な患者体験を向上させます。さらに、最先端の画像診断法と診断ツールは早期発見を容易にし、膀胱がんの予後を向上させる重大な要因となっています。これらの技術の進歩は、世界の膀胱がん市場の成長と将来性を形成する最前線にあります。

政府の取り組み

世界中の政府は、膀胱がんに対する認識を高めるために、さまざまな組織とのパートナーシップなどのさまざまな取り組みに積極的に関与しています。このような取り組みには、公衆衛生キャンペーンの展開、教育プログラムの実施、研究活動の支援などが含まれます。啓発を優先することで、政府と協力団体は、危険因子、症状、早期発見、膀胱がんの管理に利用可能な情報源について大衆を教育することを目指しています。これにより、この疾患に対する理解が深まり、予防策を取り入れたり、迅速な診察を受けたりする動機付けとなります。認知度の向上は、最終的には早期診断、治療成績の改善、医療制度への負担の軽減につながり、膀胱がんとの闘いにおけるこうした世界的な取り組みの重要性を強調しています。

当レポートでは、世界の膀胱がん市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の膀胱がん市場の見通し（2017年～2031年）

  • 市場規模と予測
    • 金額
    • 数量
  • タイプ別
    • 尿路上皮がん
    • 腺がん
    • 扁平上皮がん
    • その他
  • モダリティ別
    • 診断
    • 治療
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • 専門クリニック
    • 薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • 南米
    • アジア太平洋
    • 中東・アフリカ
  • 市場シェア：企業別（2023年）

第5章 世界の膀胱がん市場の見通し：地域別（2017年～2031年）

  • 北米
    • 市場規模と予測
    • タイプ別
    • モダリティ別
    • エンドユーザー別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第6章 市場マッピング（2023年）

  • タイプ別
  • モダリティ別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制枠組みとイノベーション

  • 臨床試験
  • 特許情勢
  • 規制当局の承認
  • イノベーション/新技術

第10章 主要企業情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析（2023年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場参入企業5社）
  • 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Johnson & Johnson Innovative Medicine
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Ferring B.V.
  • Seagen Inc.
  • Asieris Pharmaceuticals
  • Bristol-Myers Squibb Company

第14章 戦略的推奨事項

第15章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 4. Global Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 5. Global Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Bladder Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 10. North America Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 11. North America Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 16. United States Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 17. United States Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 21. Canada Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 22. Canada Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 26. Mexico Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 27. Mexico Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 31. Europe Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 32. Europe Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 37. Germany Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 38. Germany Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 42. France Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 43. France Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 47. Italy Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 48. Italy Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 52. United Kingdom Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 53. United Kingdom Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 57. Russia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 58. Russia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 62. Netherlands Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 63. Netherlands Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 67. Spain Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 68. Spain Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 72. Turkey Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 73. Turkey Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 77. Poland Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 78. Poland Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 82. South America Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 83. South America Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 88. Brazil Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 89. Brazil Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 93. Argentina Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 94. Argentina Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 98. Asia-Pacific Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 99. Asia-Pacific Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. India Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 104. India Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 105. India Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 109. China Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 110. China Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 114. Japan Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 115. Japan Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 119. Australia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 120. Australia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 124. Vietnam Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 125. Vietnam Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 129. South Korea Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 130. South Korea Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 134. Indonesia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 135. Indonesia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 139. Philippines Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 140. Philippines Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 144. Middle East & Africa Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 145. Middle East & Africa Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 150. Saudi Arabia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 151. Saudi Arabia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 155. UAE Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 156. UAE Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 160. South Africa Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 161. South Africa Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Types Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX10894

Global bladder cancer market size was valued at USD 4.51 billion in 2023, which is expected to reach USD 6.81 billion in 2031, with a CAGR of 5.28% for the forecast period between 2024 and 2031. Numerous factors are propelling the global bladder cancer market, such as the increasing prevalence of bladder cancer, the growing geriatric population, technological advancements in diagnostic and treatment methodologies, government initiatives, and increasing funding for research and development. The rising prevalence of bladder cancer is a significant factor driving the global bladder cancer market.

Bladder cancer ranks as the 10th most common cancer worldwide. It can be attributed to various factors, including an aging population and increased exposure to environmental carcinogens. As the global population ages, the risk of bladder cancer increases, creating a growing demand for diagnostic and treatment options. Advancements in healthcare infrastructure and growing accessibility are contributing to the growth of global bladder cancer market. Better access to healthcare services, higher quality of care, and advanced facilities can lead to early detection and better outcomes for bladder cancer patients.

Innovations in imaging technologies, non-invasive urine tests, and molecular diagnostics have revolutionized early detection and monitoring, leading to better patient outcomes. Increasing consumption of tobacco and increased exposure to industrial chemicals play a significant role in bladder cancer development, surging the demand for the global bladder cancer market. The market is witnessing technological advancements such as minimally invasive surgical techniques, robotic-assisted surgery, and precision medicine which improves the effectiveness of treatments and enhance patient experiences. Government initiatives and research funding are contributing to market expansion. Growing investment in bladder cancer research, including clinical trials and drug development, is expediting innovation and introducing new therapies and diagnostic tools.

Rising Prevalence of Bladder Cancer

The increasing incidence and prevalence of bladder cancer play a significant role in the expansion of the global bladder cancer market. Bladder cancer, recognized as the 6th most widespread form of cancer worldwide, presents a distinct gender divide, with it being the 10th most common cancer among men and the 17th most prevalent among women. The high prevalence is shaped by a multitude of factors, including the aging population, heightened exposure to environmental carcinogens, and individual lifestyle choices. As the number of bladder cancer cases continues to rise, there is an increasing demand for advanced diagnostic techniques, treatment modalities, and healthcare provisions. The surge in demand stimulates research, fosters innovation, and attracts investments in the bladder cancer market, geared towards enhancing early detection, more advanced therapies, and increased patient care.

Technological Advancements

Recent technological advancements are pivotal in driving the global bladder cancer market forward. These medical technology innovations have revolutionized how bladder cancer is diagnosed, treated, and monitored. They encompass the creation of less invasive surgical techniques, the incorporation of precision-enhancing robotic-assisted surgery, and the introduction of personalized medicine approaches. These breakthroughs enhance treatments' efficacy and the overall patient experience by reducing invasiveness and speeding up recovery. Additionally, state-of-the-art imaging methods and diagnostic tools are facilitating early detection, which is a critical factor in enhancing bladder cancer outcomes. These technological advancements are at the forefront of shaping the growth and potential of the global bladder cancer market. UC San Diego Health became the first healthcare system to provide a new technology that uses white light, blue light, and an imaging dye that causes cancer cells to glow fluorescent pink to identify and monitor bladder cancer in both clinic and operating room settings in San Diego.

Government Initiatives

Governments around the globe are actively involved in various initiatives such as partnerships with various organizations to increase awareness about bladder cancer. These initiatives encompass the deployment of public health campaigns, the implementation of educational programs, and the provision of support for research endeavors. By prioritizing awareness, governments and collaborating organizations aim to educate the public about risk factors, symptoms, early detection, and the available resources for managing bladder cancer. It fosters a deeper understanding of the disease and motivates individuals to embrace preventive measures and seek prompt medical attention. Enhanced awareness can ultimately result in earlier diagnoses, improved treatment outcomes, and a decreased burden on healthcare systems, underscoring the significance of these global initiatives in the battle against bladder cancer.

Fight Bladder Cancer UK, a proactive national organization driven by patients, hosted a parliamentary event in May 2023. Fight Bladder Cancer places a strong emphasis on the significance of timely screening, urging people to remain vigilant regarding possible symptoms and promptly consult a healthcare professional. It involves raising awareness among healthcare practitioners about identifying early indicators and implementing effective diagnostic procedures.

Transitional Cell Carcinoma Dominated the Market

The global bladder cancer market is witnessing a surging need for treatments custom-tailored for transitional cell carcinoma (TCC). This type of bladder cancer comprises a substantial share of all bladder cancer cases. The growing demand can be ascribed to multiple factors, including the rising incidence of transitional cell carcinoma, advancements in diagnostic techniques enabling more precise TCC detection, and an increased emphasis on individualized treatment strategies. As awareness and comprehension of the distinctive attributes and treatment requisites of TCC broaden, pharmaceutical companies and healthcare providers are allocating resources to research and therapies that address the specific needs of this subset of bladder cancer patients.

In April 2023, the Japanese multinational pharmaceutical company Astellas Pharma disclosed that Food and Drug Administration (FDA) had issued accelerated approval for Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) for the initial treatment of adults with locally advanced or metastatic transitional cell carcinoma who are not suitable candidates for cisplatin-containing chemotherapy.

Future Market Scenario

The outlook for the global bladder cancer market appears highly promising, owing to its exceptional opportunities. Bladder cancer ranks amongst the most prevalent cancers globally, rendering it a central focus for pharmaceutical and biotechnology firms. The increasing incidence of bladder cancer, influenced by factors such as an aging population, environmental factors, and evolving lifestyles, fuels a rising demand for innovative diagnostic tools and therapeutic interventions.

Furthermore, significant technological advancements have reshaped the landscape such as introduction of new treatments, precision medicine, and less invasive surgical methods that enhance patient outcomes. Strategic alliances and acquisitions among major industry players further amplify the market's growth potential, which stimulates collaborative research and development endeavors. With an expanding awareness and comprehension of bladder cancer, the market is primed to make substantial strides in the pursuit of more efficacious treatments, early detection, and enhanced patient care.

Key Players Landscape and Outlook

In the global bladder cancer market, prominent pharmaceutical and biotechnology firms are progressively entering into strategic alliances to seize the extensive prospects. These partnerships allow these companies to merge their knowledge, resources, and research endeavors, with the goal of creating innovative diagnostic tools, therapies, and treatment solutions. Moreover, these collaborative efforts facilitate the exchange of expertise and cutting-edge technologies, which are vital in addressing the intricacies of bladder cancer. By consolidating their capabilities, these companies aspire to expedite the development of pharmaceuticals, improve patient care, and meet the unfulfilled medical requirements in the domain. Ultimately, these partnerships empower the industry to cater to the escalating demand more effectively for bladder cancer treatments and diagnostic methods.

In October 2023, the European Union approved the acquisition of the biotechnology company Seagen, which specializes in innovative cancer treatments by Pfizer. The deal, valued at USD 43 billion, is set to broaden Pfizer's range of bladder cancer medications through the incorporation of Seagen's therapies.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Bladder Cancer Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Types
    • 4.2.1. Urothelial Carcinoma
    • 4.2.2. Adenocarcinoma
    • 4.2.3. Squamous Cell Carcinoma
    • 4.2.4. Others
  • 4.3. By Modality
    • 4.3.1. Diagnosis
      • 4.3.1.1. Cytology
      • 4.3.1.2. Cystoscopy
      • 4.3.1.3. MRI Scan
      • 4.3.1.4. CT Scan
    • 4.3.2. Treatment
      • 4.3.2.1. Surgery
      • 4.3.2.2. Radiation Therapy
      • 4.3.2.3. Radiopharmaceuticals
      • 4.3.2.4. Transurethral Bladder Tumour Resection
      • 4.3.2.5. Chemotherapy
      • 4.3.2.6. Immunotherapy
      • 4.3.2.7. Gene Therapy
      • 4.3.2.8. Cryotherapy
      • 4.3.2.9. High-Intensity Focused Ultrasound
      • 4.3.2.10. Targeted Therapy
  • 4.4. By End-user
    • 4.4.1. Hospitals
    • 4.4.2. Ambulatory Surgical Centers
    • 4.4.3. Specialty Clinics
    • 4.4.4. Pharmacies
    • 4.4.5. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. South America
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Bladder Cancer Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Types
      • 5.1.2.1. Urothelial Carcinoma
      • 5.1.2.2. Adenocarcinoma
      • 5.1.2.3. Squamous Cell Carcinoma
      • 5.1.2.4. Others
    • 5.1.3. By Modality
      • 5.1.3.1. Diagnosis
      • 5.1.3.1.1. Cytology
      • 5.1.3.1.2. Cystoscopy
      • 5.1.3.1.3. MRI Scan
      • 5.1.3.1.4. CT Scan
      • 5.1.3.2. Treatment
      • 5.1.3.2.1. Surgery
      • 5.1.3.2.2. Radiation Therapy
      • 5.1.3.2.3. Radiopharmaceuticals
      • 5.1.3.2.4. Transurethral Bladder Tumour Resection
      • 5.1.3.2.5. Chemotherapy
      • 5.1.3.2.6. Immunotherapy
      • 5.1.3.2.7. Gene Therapy
      • 5.1.3.2.8. Cryotherapy
      • 5.1.3.2.9. High-Intensity Focused Ultrasound
      • 5.1.3.2.10. Targeted Therapy
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Ambulatory Surgical Centers
      • 5.1.4.3. Specialty Clinics
      • 5.1.4.4. Pharmacies
      • 5.1.4.5. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size and Forecast
      • 5.1.5.1.1. Value
      • 5.1.5.1.2. Volume
      • 5.1.5.2. By Types
      • 5.1.5.2.1. Urothelial Carcinoma
      • 5.1.5.2.2. Adenocarcinoma
      • 5.1.5.2.3. Squamous Cell Carcinoma
      • 5.1.5.2.4. Others
      • 5.1.5.3. By Modality
      • 5.1.5.3.1. Diagnosis
      • 5.1.5.3.1.1. Cytology
      • 5.1.5.3.1.2. Cystoscopy
      • 5.1.5.3.1.3. MRI Scan
      • 5.1.5.3.1.4. CT Scan
      • 5.1.5.3.2. Treatment
      • 5.1.5.3.2.1. Surgery
      • 5.1.5.3.2.2. Radiation Therapy
      • 5.1.5.3.2.3. Radiopharmaceuticals
      • 5.1.5.3.2.4. Transurethral Bladder Tumour Resection
      • 5.1.5.3.2.5. Chemotherapy
      • 5.1.5.3.2.6. Immunotherapy
      • 5.1.5.3.2.7. Gene Therapy
      • 5.1.5.3.2.8. Cryotherapy
      • 5.1.5.3.2.9. High-Intensity Focused Ultrasound
      • 5.1.5.3.2.10. Targeted Therapy
      • 5.1.5.4. By End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Ambulatory Surgical Centers
      • 5.1.5.4.3. Specialty Clinics
      • 5.1.5.4.4. Pharmacies
      • 5.1.5.4.5. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Types
  • 6.2. By Modality
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Astellas Pharma Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. AstraZeneca plc
  • 13.3. Johnson & Johnson Innovative Medicine
  • 13.4. Bayer AG
  • 13.5. Merck & Co., Inc.
  • 13.6. Pfizer, Inc.
  • 13.7. Ferring B.V.
  • 13.8. Seagen Inc.
  • 13.9. Asieris Pharmaceuticals
  • 13.10. Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer